Asian registry of brachytherapy for cervical cancer

Asian Gynecological Brachytherapy Registry in Cervical Cancer

This project will see how different internal radiation (brachytherapy) approaches are used and perform for people in Asia with stage IB–IVA cervical cancer treated with chemoradiation.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Sex: Female
• Sponsor: Tata Memorial Hospital (other gov)
• Drugs / interventions: radiation, chemotherapy
• Locations: 5 sites (Mumbai, Maharashtra and 4 other locations)
• Trial ID: NCT07196033 on ClinicalTrials.gov

What this trial studies

The registry uses a retrospective cohort design to collect consecutive cases from participating Asian centers over a 12‑month period, aiming for about 1,000 patients. It captures the full range of brachytherapy practice (2D to 3D), imaging modalities used for planning (X‑ray, CT, MRI, ultrasound), external beam radiation details, concurrent chemotherapy, and overall treatment time. Patient demographics, contouring practices, and institutional treatment patterns will be recorded, with monitoring and quality assurance procedures to ensure data completeness and integrity. Data handling protocols will protect privacy and a publication policy will guide multi‑institutional analysis and reporting.

Who should consider this trial

Good fit: People with FIGO 2018 stage IB–IVA cervical cancer (squamous, adenocarcinoma, or adenosquamous histology) who were planned for definitive chemoradiation including brachytherapy are ideal candidates for inclusion.

Not a fit: Patients with neuroendocrine or other rare histologies, those with metastatic disease not planned for radical pelvic RT/brachytherapy, or those receiving postoperative or recurrent‑disease radiotherapy are unlikely to benefit from inclusion in this registry.

Why it matters

Potential benefit: If successful, the registry could identify brachytherapy practices linked to better tumor control and fewer side effects and help centers across Asia standardize and improve care.

How similar studies have performed: Advanced brachytherapy techniques have produced strong outcomes in Europe and North America, but large multi‑centre registries documenting real‑world Asian practice are limited, so this effort is building on known techniques but filling a regional data gap.

Eligibility criteria

Inclusion Criteria:

* Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype.
* Planned for treatment with definitive chemo-radiation and brachytherapy. (X- ray,CT, CT-Ultrasound or MRI based).

Exclusion Criteria:

* Neuroendocrine cancer of the cervix or other rare histology subtypes.
* Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT/brachytherapy may be excluded.
* Patients undergoing postoperative RT or RT for recurrent disease should be excluded.

Where this trial is running

Mumbai, Maharashtra and 4 other locations

• Tata Memorial Center — Mumbai, Maharashtra, India (RECRUITING)
• Gunma University — Maebashi, Japan, Japan (NOT_YET_RECRUITING)
• Juntendo University — Tokyo, Japan, Japan (NOT_YET_RECRUITING)
• Mahidol University — Bangkok, Thailand, Thailand (NOT_YET_RECRUITING)
• Chiang Mai University — Chiang Mai, Thailand, Thailand (NOT_YET_RECRUITING)

Study contacts

• Study coordinator: Dr. Supriya Chopra

Conditions: Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Definitive chemo-radiation, Brachytherapy